Liquidia Technologies LQDA 深 沪
已收盘 12-19 16:00:00 美东时间
34.51
+0.840
+2.49%
华盛通- 最 高35.54
- 今 开33.63
- 成交量 124.64万股
- 最 低 30.00
- 昨 收 33.67
- 总市值 22.21亿
- 52周最高 35.54
- 市盈率 静 --
- 换手率 1.94%
- 52周最低 11.26
- 委 比 79.27%
- 总股本 6434.45万
- 历史最高 38.46
- 量 比 1.35
- 振 幅 16.45%
- 历史最低 1.10
- 每 手 1
- 风险率 6.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
Liquidia's YUTREPIA, a treprostinil inhalation powder for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), is now available via specialty pharmacies following FDA approval on May 23, 2025. The commercial launch was achieved in just five business days and court denied a preliminary injunction against it. YUTREPIA aims to provide a new treatment option for patients with these conditions.
06-02 10:30
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
Liquidia Corporation executives will discuss the company's progress at the 2025 Jefferies Global Healthcare Conference on June 4, 2025, in New York City. A webcast and archived recording will be available on their website.
05-28 12:00
Nasdaq Surges Over 200 Points; US Crude Oil Stocks Increase
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite g...
2024-09-12 02:30
Liquidia Announces Raise Of $67.5M From New Common Stock Financings From The Sale Of 6,460,674 Shares Of Common Stock At A Price Of $8.90 Per Share; And $32.5M Advance From HealthCare Royalty Under Current Financing Agreement
Liquidia Corporation (NASDAQ:LQDA) (the "Company" or "Liquidia"), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the pricing of an
2024-09-11 20:29
Liquidia Seeks Stay on FDA Exclusivity Approval of Rival Version of Hypertension Drug
05:42 PM EDT, 08/28/2024 (MT Newswires) -- Liquidia (LQDA) is seeking a preliminary injunction on an Aug. 16 decision by the US Food and Drug Administration to keep its Yutrepia drug off the market until the exclusivity period for a rival medication expires May next year, according to court document...
2024-08-29 05:42
HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $29 price target.
2024-08-23 19:17
Liquidia Files Legal Challenge Against FDA Decision to Grant 3-Year New Clinical Investigation Exclusivity to Tyvaso DPI
07:09 AM EDT, 08/22/2024 (MT Newswires) -- Liquidia (LQDA) said Thursday it has filed a legal challenge to the US Food and Drug Administration's recent decision to grant a three-year new clinical investigation exclusivity to United Therapeutics' (UTHR) Tyvaso DPI. The complaint was filed with the US...
2024-08-22 19:09
Liquidia Has Filed Litigation In The U.S. District Court Of The District Of Columbia That Challenges The Recent FDA Decision To Grant 3-year New Clinical Investigation Exclusivity (NCI Exclusivity) To Tyvaso DPI
FDA granted tentative approval of YUTREPIA (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) patients on August 16, 2024. As a result of the FDA's award of NCI exclusivity to Tyvaso DPI, the f...
2024-08-22 18:05
